APA (7th ed.) Citation

Bang, Y., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., . . . Kang, Y. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. The lancet, 376(9742), . https://doi.org/10.1016/S0140-6736(10)61121-X

Chicago Style (17th ed.) Citation

Bang, Yung-Jue, et al. "Trastuzumab in Combination with Chemotherapy Versus Chemotherapy Alone for Treatment of HER2-positive Advanced Gastric or Gastro-oesophageal Junction Cancer (ToGA): A Phase 3, Open-label, Randomised Controlled Trial." The Lancet 376, no. 9742 (2010). https://doi.org/10.1016/S0140-6736(10)61121-X.

MLA (9th ed.) Citation

Bang, Yung-Jue, et al. "Trastuzumab in Combination with Chemotherapy Versus Chemotherapy Alone for Treatment of HER2-positive Advanced Gastric or Gastro-oesophageal Junction Cancer (ToGA): A Phase 3, Open-label, Randomised Controlled Trial." The Lancet, vol. 376, no. 9742, 2010, https://doi.org/10.1016/S0140-6736(10)61121-X.